1. Home
  2. KBDC vs CDTX Comparison

KBDC vs CDTX Comparison

Compare KBDC & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KBDC
  • CDTX
  • Stock Information
  • Founded
  • KBDC 2021
  • CDTX 2012
  • Country
  • KBDC United States
  • CDTX United States
  • Employees
  • KBDC N/A
  • CDTX N/A
  • Industry
  • KBDC
  • CDTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • KBDC
  • CDTX Health Care
  • Exchange
  • KBDC Nasdaq
  • CDTX Nasdaq
  • Market Cap
  • KBDC 1.1B
  • CDTX 980.1M
  • IPO Year
  • KBDC N/A
  • CDTX 2015
  • Fundamental
  • Price
  • KBDC $16.07
  • CDTX $48.89
  • Analyst Decision
  • KBDC Buy
  • CDTX Strong Buy
  • Analyst Count
  • KBDC 4
  • CDTX 11
  • Target Price
  • KBDC $16.38
  • CDTX $52.11
  • AVG Volume (30 Days)
  • KBDC 136.2K
  • CDTX 1.4M
  • Earning Date
  • KBDC 08-11-2025
  • CDTX 08-12-2025
  • Dividend Yield
  • KBDC 11.77%
  • CDTX N/A
  • EPS Growth
  • KBDC N/A
  • CDTX N/A
  • EPS
  • KBDC N/A
  • CDTX N/A
  • Revenue
  • KBDC N/A
  • CDTX $302,000.00
  • Revenue This Year
  • KBDC $193.84
  • CDTX N/A
  • Revenue Next Year
  • KBDC $12.68
  • CDTX N/A
  • P/E Ratio
  • KBDC N/A
  • CDTX N/A
  • Revenue Growth
  • KBDC N/A
  • CDTX N/A
  • 52 Week Low
  • KBDC $13.93
  • CDTX $10.14
  • 52 Week High
  • KBDC $17.99
  • CDTX $56.83
  • Technical
  • Relative Strength Index (RSI)
  • KBDC N/A
  • CDTX 73.52
  • Support Level
  • KBDC N/A
  • CDTX $45.59
  • Resistance Level
  • KBDC N/A
  • CDTX $52.33
  • Average True Range (ATR)
  • KBDC 0.00
  • CDTX 5.13
  • MACD
  • KBDC 0.00
  • CDTX 0.22
  • Stochastic Oscillator
  • KBDC 0.00
  • CDTX 61.27

About KBDC Kayne Anderson BDC Inc. Common Stock

Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.

About CDTX Cidara Therapeutics Inc.

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Share on Social Networks: